You just read:

TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa

News provided by

TWi Biotechnology, Inc.

Feb 26, 2018, 03:58 ET